European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint

Aimmune Therapeutics (AIMT) PT Raised to $58 at RBC Capital

March 26, 2019 6:27 AM EDT

RBC Capital analyst Kennen MacKay raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $58.00 (from $55.00) while maintaining a Outperform rating.

ARTEMIS reads out positively in Europesetting the stage for a mid-19 MAA filing... More

Baird Incrementally Positive on Aimmune Therapeutics (AIMT) ARTEMIS Topline Readout

March 25, 2019 12:52 PM EDT

Baird analyst Brian Skorney reiterated an Outperform rating and $64.00 price target on Aimmune Therapeutics (NASDAQ: AIMT) saying they are incrementally positive on ARTEMIS topline readout.

Skorney commented, "Aimmune announced today that the Phase 3 European trial of AR101 met its primary endpoint,... More